Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gefitinib - AstraZeneca

Next Previous
Drug Profile

Gefitinib - AstraZeneca

Alternative Names: Iressa; ZD 1839

Latest Information Update: 17 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Brigham and Women's Hospital; Dana-Farber Cancer Institute; Hutchison MediPharma; Massachusetts General Hospital; MedImmune; Netherlands Cancer Institute; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Morpholines; Phenyl ethers; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Colorectal cancer; Salivary gland cancer
  • No development reported Head and neck cancer
  • Discontinued Bladder cancer; Brain metastases; Breast cancer; Glioblastoma; Renal cell carcinoma; Thyroid cancer

Most Recent Events

  • 26 Sep 2018 AstraZeneca and Massachusetts General Hospital completes a phase I/II trial in Non-small cell lung cancer (Late-stage disease, Combination therapy, Metastatic disease) in Singapore (PO) (NCT00809237)
  • 24 Jun 2018 Biomarkers information updated
  • 28 May 2018 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top